Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Operations Update

16 Oct 2013 07:00

RNS Number : 5998Q
Eland Oil & Gas PLC
16 October 2013
 



 

16 October 2013

 

Eland Oil & Gas PLC

 ("Eland" or the "Company")

 

Operations Update

 

Eland Oil & Gas PLC (AIM: ELA), an oil & gas development and exploration company operating in West Africa with an initial focus on Nigeria, announces the following update on activities for the OML 40 licence, located onshore Nigeria ("OML 40").

 

HIGHLIGHTS

 

 

· The Opuama Production Facility was shut down in March 2006 and consequently there has been some deterioration of infrastructure. Eland have worked closely with the Operator (NPDC) to re-start the production in a challenging operating environment. This joint approach has ensured that the complex issues have been addressed collectively and resolved to provide the best opportunity for an early restart of production on the facility which has been shut in for 7 years. Operational activities in 2013 have therefore been initially focused on replacement of the corroded infield flowlines, refurbishment of the production flowstation and the repair of the oil export pipeline including the replacement of all corroded and damaged sections.

 

· The work of fabrication and installation has been completed to fully replace the 3 flowlines on the planned existing start-up wells in the Opuama Field. These flowlines have been trenched and overlaid with protective concrete mats at major water crossings. A cathodic protection system has also been installed.

 

· The 8" and 10" sections of the export pipeline have been surveyed and repaired (first 12km of 36km). This section of the line is currently being flushed prior to conducting a full pressure test to verify its integrity. The repairs to the final 24km-long 12" section to Otumara (custody transfer point) are on-going and expected to complete within the next 3-4 weeks.

 

· The Opuama Flowstation Rehabilitation work is currently underway with purchasing of the major components ongoing and site activities starting The work program is expected to have a 3-5 week duration.

 

· With these final works expected to complete over the coming weeks, management is confident that production will commence before year end. While this is a deferment from the previously prognosed October, comfort can be drawn from the fact that work on all components is underway and is being vigorously monitored for ways of improvement.

 

· Drilling of the initial six development wells within the Opuama Field (Gross Certified 2P Reserves of 54.2 Million bbls) is planned to commence upon the release of the Depthwize Imperial swamp rig currently on a single well assignment with Conoil on OPL 2007. The latest information from the current operator indicates that the Rig should be released from location in early 2014.

 

· Year-end exit production rate is anticipated to be in excess of 2,500 bopd from the planned restart of the two existing wells in the Opuama Field. It is then anticipated that production will increase by circa 3,000 bopd for each subsequent new well drilled during 2014. These wells will be hooked up to the production facility as they are drilled.

 

· The agreed debt facilities with Standard Chartered Bank remain available following first oil and the Company currently has sufficient cash to meet first oil requirements.

 

 

Les Blair, CEO of Eland Oil & Gas, commented:

"Our immediate focus is to restore oil production on OML 40 and we have a close working relationship with the Operator, NPDC, to achieve this goal. In parallel we continue planning for the extensive development drilling campaign on OML 40, starting with six wells on the Opuama Field.

The delays we have experienced are frustrating but not unexpected in a project of this complexity and in the environment in which we are operating. The management of Eland have significant experience of working in Nigeria and have established excellent working relationships with NPDC and all of our stakeholders in the license area. This will stand the Company in good stead to unlock the value inherent in OML 40, which will be amply demonstrated when the drilling campaign gets underway."

 

For further information:

 

Eland Oil & Gas PLC (+44 (0) 207 016 3180)

Les Blair, CEO

George Maxwell, CFO

Edward Cozens, IR

 

Canaccord Genuity Limited (+44 (0) 207 523 8000)

Henry Fitzgerald-O'Connor

Peter Stewart

 

FirstEnergy Capital LLP (+44 (0) 207 448 0200)

Majid Shafiq

Khalid Ahmed

 

Citigate Dewe Rogerson (+44 (0) 207 638 9571)

Martin Jackson

Jack Rich

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDDBDGDUBBGXU
Date   Source Headline
17th Jul 20095:57 pmBUSStudies Presented at International Conference on Alzheimer's Disease Reveal Substantial Economic Costs and Caregiver Burden Associated with Alzheimer's Disease
16th Jul 20092:18 pmRNSResults of Annual General Meeting
13th Jul 200911:30 amBUSElan and Transition Therapeutics Announce Phase 1 Data Showing ELND005 Achieves Desired Concentrations in Brain Tissue and Cerebrospinal Fluid
10th Jul 20094:59 pmRNSCancellation of UK Listing
8th Jul 20097:00 amBUSElan Announces Webcast of Second Quarter 2009 Financial Results
3rd Jul 200910:57 amRNSBlock Listing Six Monthly Return
2nd Jul 200912:57 pmRNSHolding in Company
2nd Jul 200912:41 pmPRNJohnson & Johnson, Elan Announce Definitive Agreement
1st Jun 20097:00 amBUSSubset Data from Two Randomized Phase 3 Trials Show TYSABRI® Significantly Improves Health-Related Quality of Life for Crohn's Disease Patients with Prior Exposure or Inadequate Response to Anti-TNF? Therapy
29th May 20094:36 pmRNSPrice Monitoring Extension
29th May 20092:00 pmBUSRenee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer
29th May 200911:54 amBUSTotal Voting Rights
30th Apr 200912:16 pmBUSTotal Voting Rights
27th Apr 20093:35 pmRNSAnnual Report
14th Apr 20095:09 pmRNSHolding(s) in Company
27th Feb 20092:44 pmBUSTotal Voting Rights
25th Feb 200912:23 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
12th Feb 20096:00 pmBUSDirector/PDMR Shareholding
9th Feb 20097:00 amBUSMS Patients Treated with TYSABRI® Remain Free of Disease Activity for Two Years, According to Data Published in the Lancet Neurology
4th Feb 20092:32 pmRNSHolding(s) in Company
3rd Feb 20093:57 pmRNSHolding(s) in Company
30th Jan 20094:33 pmRNSHolding(s) in Company
28th Jan 20094:24 pmRNSHolding(s) in Company
13th Jan 20097:00 amBUSElan Clarifies Duration of Bapineuzumab Phase 3 Trials
12th Jan 20095:21 pmRNSHolding(s) in Company
12th Jan 20097:00 amBUSTysabri Update
2nd Jan 200912:21 pmRNSTotal Voting Rights
18th Dec 20084:24 pmRNSBlock Listing Six Monthly Return
16th Dec 200811:00 amBUSDirector Declaration
16th Dec 20087:00 amBUSElan to Present at the 27th Annual JP Morgan Healthcare Conference
15th Dec 20083:02 pmBUSTysabri Update
12th Dec 20087:00 amBUSElan Announces Resource Realignment
28th Nov 200810:47 amBUSTotal Voting Rights
25th Nov 20087:00 amBUSMary Stutts to Join Elan as Senior Vice President and Head of Corporate Relations
20th Nov 20087:00 amBUSCarlos V. Paya, MD, PhD, to Join Elan as Company President
3rd Nov 20085:12 pmRNSDirector/PDMR Shareholding
31st Oct 20084:11 pmRNSHolding in Company
31st Oct 200812:01 pmRNSTotal Voting Rights
30th Oct 20084:13 pmRNSTysabri Update
3rd Oct 20085:56 pmRNSHolding in Company
30th Sep 20084:11 pmRNSTotal Voting Rights
22nd Sep 200811:26 amRNSHolding In Company
22nd Sep 20087:00 amRNSTysabri Demonstrates Sustained Improvement
11th Sep 20087:39 amRNSDirector /PDMR Shareholding
1st Sep 20085:02 pmRNSHolding(s) in Company
29th Aug 200810:54 amRNSTotal Voting Rights
28th Aug 20087:00 amRNSInterim Results
14th Aug 20084:12 pmRNSHolding in Company
13th Aug 20085:22 pmRNSHolding in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.